Thomas F. Marandu

Dr. Thomas F. Marandu

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Experimental Gerontology
Verified
Journal Article
Open access
PSPaolo Sansoni
Paolo Sansoni
RVRosanna Vescovini
Rosanna Vescovini
FFFrancesco F. Fagnoni
Francesco F. Fagnoni
AAArne Akbar
Arne Akbar
RARamon Arens
Ramon Arens
JNJanko Nikolich-Žugich
Janko Nikolich-Žugich
Immunosenescence, defined as the age-associated dysregulation and dysfunction of the immune system, is characterized by impaired protective immunity and decreased efficacy of vaccines. An increasing number of immunological, clinical and epidemiological studies suggest that persistent Cytomegalovirus (CMV) infection is associated with accelerated aging of the immune system and with several age-related diseases. However, current evidence on whether and how human CMV (HCMV) infection is implicated in immunosenescence and in age-related diseases remains incomplete and many aspects of CMV involvement in immune aging remain controversial. The attendees of the 4th International Workshop on "CMV & Immunosenescence", held in Parma, Italy, 25-27th March, 2013, presented and discussed data related to these open questions, which are reported in this commentary.

16 August 2012 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
LCLuka Cicin-Sain
Luka Cicin-Sain
JBJames D. Brien
James D. Brien
JUJennifer L. Uhrlaub
Jennifer L. Uhrlaub
ADAnja Drabig
Anja Drabig
TMThomas F. Marandu
Thomas F. Marandu
JNJanko Nikolich-Žugich
Janko Nikolich-Žugich
Prominent immune alterations associated with aging include the loss of naïve T-cell numbers, diversity and function. While genetic contributors and mechanistic details in the aging process have been addressed in multiple studies, the role of environmental agents in immune aging remains incompletely understood. From the standpoint of environmental infectious agents, latent cytomegalovirus (CMV) infection has been associated with an immune risk profile in the elderly humans, yet the cause-effect relationship of this association remains unclear. Here we present direct experimental evidence that mouse CMV (MCMV) infection results in select T-cell subset changes associated with immune aging, namely the increase of relative and absolute counts of CD8 T-cells in the blood, with a decreased representation of the naïve and the increased representation of the effector memory blood CD8 T-cells. Moreover, MCMV infection resulted in significantly weaker CD8 responses to superinfection with Influenza, Human Herpes Virus I or West-Nile-Virus, even 16 months following MCMV infection. These irreversible losses in T-cell function could not be observed in uninfected or in vaccinia virus-infected controls and were not due to the immune-evasive action of MCMV genes. Rather, the CD8 activation in draining lymph nodes upon viral challenge was decreased in MCMV infected mice and the immune response correlated directly to the frequency of the naïve and inversely to that of the effector cells in the blood CD8 pool. Therefore, latent MCMV infection resulted in pronounced changes of the T-cell compartment consistent with impaired naïve T-cell function. The cytomegalovirus (CMV) is a widespread virus of the herpesvirus family, which latently infects the majority of the adult human population worldwide. While CMV causes severe disease in AIDS patients, in recipients of organ transplants, or when infection occurs during pregnancy, this virus is considered apathogenic for the general population. Several reports indicated that CMV infection may be associated with poor immune function, and even survival, in older adults, yet it remained unclear whether CMV infection may have the potential to impair the immune function. Here we test this possibility in a mouse model of CMV (MCMV) infection. We found that mice carrying latent MCMV exhibit significant changes in CD8+ lymphocytes, which are crucial in the recognition of, and protection against viruses. These changes were similar to changes observed in aging and resulted in poor cytotoxic T-lymphocyte response to infection with unrelated viruses, such as the West Nile virus or the influenza virus. Our study provides the first experimental demonstration that latent CMV infection may impair the immune defense of the host.

15 December 2016 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
IDIryna Dekhtiarenko
Iryna Dekhtiarenko
RRRobert B Ratts
Robert B Ratts
RBRenata Blatnik
Renata Blatnik
LLLian N Lee
Lian N Lee
SFSonja Fischer
Sonja Fischer
LCLuka Cicin-Sain
Luka Cicin-Sain
Cytomegalovirus (CMV) elicits long-term T-cell immunity of unparalleled strength, which has allowed the development of highly protective CMV-based vaccine vectors. Counterintuitively, experimental vaccines encoding a single MHC-I restricted epitope offered better immune protection than those expressing entire proteins, including the same epitope. To clarify this conundrum, we generated recombinant murine CMVs (MCMVs) encoding well-characterized MHC-I epitopes at different positions within viral genes and observed strong immune responses and protection against viruses and tumor growth when the epitopes were expressed at the protein C-terminus. We used the M45-encoded conventional epitope HGIRNASFI to dissect this phenomenon at the molecular level. A recombinant MCMV expressing HGIRNASFI on the C-terminus of M45, in contrast to wild-type MCMV, enabled peptide processing by the constitutive proteasome, direct antigen presentation, and an inflation of antigen-specific effector memory cells. Consequently, our results indicate that constitutive proteasome processing of antigenic epitopes in latently infected cells is required for robust inflationary responses. This insight allows utilizing the epitope positioning in the design of CMV-based vectors as a novel strategy for enhancing their efficacy. Experimental cytomegalovirus (CMV) based vaccine vectors have provided highly encouraging results as innovative vaccine formulations against deadly virus infections, such as Ebola or AIDS. Nevertheless, it has remained incompletely understood why CMV is so efficient at stimulating T-lymphocytes, the immune cells that recognize pathogens within infected cells. We have generated an array of CMV mutants expressing the same antigen in different genes or in different parts of the same gene. This allowed us to identify that the immediate environment of the antigen, rather than properties of the antigen itself, crucially determine the immune protection conferred by CMV-based vaccines, implying that optimal immunity depends on the ability of host cells to degrade CMV proteins into peptides, short units that are recognized by T-cells. Detailed analysis revealed that strong and sustained T-cell immunity occurs only when their antigenic targets are processed by a primitive cellular machinery that is present in all cells of the body, rather than by its newly-evolved counterpart, which is present only in specialized antigen-presenting cells. Most importantly, our results provide a simple strategy to develop improved CMV vaccines by positioning the antigenic peptides at the right spot in CMV proteins.

1 January 2016 in Journal of General Virology
Verified
Journal Article
Closed access
JOJennifer D. Oduro
Jennifer D. Oduro
ARAnke Redeker
Anke Redeker
Niels LemmermannNiels Lemmermann
Niels Lemmermann
LELinda Ebermann
Linda Ebermann
TMThomas F. Marandu
Thomas F. Marandu
LCLuka Cicin-Sain
Luka Cicin-Sain
Cytomegalovirus (CMV) is a ubiquitous virus, causing the most common congenital infection in humans, yet a vaccine against this virus is not available. The experimental study of immunity against CMV in animal models of infection, such as the infection of mice with the mouse CMV (MCMV), has relied on systemic intraperitoneal infection protocols, although the infection naturally transmits by mucosal routes via body fluids containing CMV. To characterize the biology of infections by mucosal routes, we have compared the kinetics of virus replication, the latent viral load, and CD8 T cell responses in lymphoid organs upon experimental intranasal and intragastric infection to intraperitoneal infection of two unrelated mouse strains. We have observed that intranasal infection induces robust and persistent virus replication in lungs and salivary glands, but a poor one in the spleen. CD8 T cell responses were somewhat weaker than upon intraperitoneal infection, but showed similar kinetic profiles and phenotypes of antigen-specific cells. On the other hand, intragastric infection resulted in abortive or poor virus replication in all tested organs, and poor T cell responses to the virus, especially at late times after infection. Consistent with the T cell kinetics, the MCMV latent load was high in the lungs, but low in the spleen of intranasally infected mice and lowest in all tested organs upon intragastric infection. In conclusion, we show here that intranasal, but not intragastric infection of mice with MCMV represents a robust model to study short and long-term biology of CMV infection by a mucosal route.

15 November 2015 in Journal of Virology
Verified
Journal Article
Open access
PDF file
TMThomas F. Marandu
Thomas F. Marandu
JOJennifer D. Oduro
Jennifer D. Oduro
LBLisa Borkner
Lisa Borkner
IDIryna Dekhtiarenko
Iryna Dekhtiarenko
JUJennifer L. Uhrlaub
Jennifer L. Uhrlaub
LCLuka Cicin-Sain
Luka Cicin-Sain
Latent herpesvirus infections alter immune homeostasis. To understand if this results in aging-related loss of immune protection against emerging infections, we challenged old mice carrying latent mouse cytomegalovirus (CMV), herpes simplex virus 1 (HSV-1), and/or murine gammaherpesvirus 68 (MHV-68) with influenza virus, West Nile virus (WNV), or vesicular stomatitis virus (VSV). We observed no increase in mortality or weight loss compared to results seen with herpesvirus-negative counterparts and a relative but not absolute reduction in CD8 responses to acute infections. Therefore, the presence of herpesviruses does not appear to increase susceptibility to emerging infections in aging patients.

11 April 2019 in Medical Microbiology and Immunology
Verified
Journal Article
Closed access
PDF file
TMThomas F. Marandu
Thomas F. Marandu
MDMichael Dombek
Michael Dombek
CCCharles Cook
Charles Cook